Biogen’s $900 million settlement signals scrutiny on speaker fees
Pharmaceutical Technology
OCTOBER 5, 2022
Bringing an end to a 13-year deliberation on a whistleblower lawsuit, Biogen recently agreed to pay a $900 million settlement , amidst increased government alertness on pharmaceutical fraud. The US government has recently prioritized the pursuit of cases such as Biogen’s as a warning to the industry to remain in compliance of the law.
Let's personalize your content